Skystar Bio-Pharmaceutical Co. (SKBI) Reports Q4 EPS of $0.13

Skystar Bio-Pharmaceutical Co. (NASDAQ: SKBI) reported Q4 EPS of $0.13, versus $0.09 reported last year. Revenue for the quarter came in at $6.83 million, versus $5.53 million reported last year.

For earnings history and earnings-related data on Skystar Bio-Pharmaceutical Co. (SKBI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery